Genethera Inc (GTHR) 0.0370 $GTHR
GENETHERA SECURES NEW LABORATORY FACILITIES TO EXPAND TECHNOLOGY PLATFORMS
GlobeNewswire - Mon Jan 25, 11:33AM CST
GeneThera Inc. (OTC: GTHR) announced today that it has secured a new laboratory facility. Dr. Tony Milici, CEO of GeneThera, stated; "This is an important step towards expanding our molecular robotics and DNA therapeutic vaccine platforms". The 8,000 square feet facility will be a fully integrated molecular robotics laboratory, which will house GeneThera IRSA robotic equipment to test milk products. It will also test Chron's disease to detect Mycobacterium Para tuberculosis in a highly sensitive way. In addition, we will have a "state-of-the-art" DNA vaccine laboratory fully dedicated to the development of Johne's and Chron's disease therapeutic vaccines." GeneThera is planning to move to the new laboratory facility once space renovation is completed. The projected moving date is presently scheduled for March 31st 2016.
GENETHERA, INC. ISSUES COMMENTS ON THE FIRST INTERNATIONAL RESEARCH SYMPOSIUM ON MAP AND CROHN'S DISEASE.
GlobeNewswire - Tue Sep 29, 8:43AM CDT
GeneThera, Inc. (OTC: GTHR) as a service to its shareholders and the general public is pleased to release comments on the first Symposium on Mycobacterium Avium Paratuberculosis (MAP) and Crohn's disease, which was held on August 15 in Deerfield (IL). The Symposium entitled Game Changing Concepts in Crohn's Medicine was the first one ever held where scientists, physicians, Crohn's patients, family members and patient advocates gathered to discuss the link between MAP and Crohn's disease. Keynote Speakers were Dr. William Chamberlin, Las Cruces, NM; John Aiken, Laboratory Scientist from New Zealand; Dr. Amy Hermon-Taylor, a Family Physician from London, UK and daughter of Prof. John Hermon-Taylor, who pioneered the field of MAP and Crohn's Disease; Patrick McLean, Product Manager of RedHill Pharma (NASDAQ: RDHL), an Israel-based biopharmaceutical company; and Dr. Michael Collins, Professor of Veterinary Medicine at the University of Wisconsin in Madison. Proceedings of the Symposium are available at www.thecrohnsinfection.org
RDHL: 10.38 (+0.26)
MYCOBACTERIUM AVIUM PARATUBERCULOSIS (MAP) INFECTION: THE GLOBAL WARMING OF THE CATTLE INDUSTRY
GlobeNewswire - Mon Aug 03, 8:38AM CDT
Despite warnings from scientists who have shown unquestionable data that Earth climate has been changing due to human activities, governments and multinational corporations for years have denied scientific evidences. MAP infection in cattle draws many similarities with global warming. Despite the fact that MAP has been linked to several human diseases, governments, the cattle and dairy industry have continued to ignore scientific data and have not implemented any credible programs to control MAP infection. In the meantime, herd prevalence of MAP infection in cattle worldwide has reached alarming levels. More than 90% of dairy herds in the US are infected. In the UK, 50% of dairy herds are infected with MAP. A recent report from the Advisory Committee on Dangerous Pathogens (ACDP), a scientific advisory board of the UK Government, concluded that MAP potential for human infection exist and is not limited to Chron's Disease (CD). The ACDP report points out that genome analysis have suggested an association between MAP and several other inflammatory diseases besides CD. These diseases are:
GENETHERA APPOINTS TWO NEW MEMBERS ON ITS BOARD OF DIRECTORS
GlobeNewswire - Tue Apr 21, 10:54AM CDT
GeneThera Inc. (OTC:GTHR) announced today that has appointed Bruce Winsett and Jorgen Frandsen as members of the Company's Board of Directors
GENETHERA SECURES NEW LABORATORY FACILITIES TO EXPAND TECHNOLOGY PLATFORMS
GlobeNewswire - Mon Jan 25, 11:33AM CST
GeneThera Inc. (OTC: GTHR) announced today that it has secured a new laboratory facility. Dr. Tony Milici, CEO of GeneThera, stated; "This is an important step towards expanding our molecular robotics and DNA therapeutic vaccine platforms". The 8,000 square feet facility will be a fully integrated molecular robotics laboratory, which will house GeneThera IRSA robotic equipment to test milk products. It will also test Chron's disease to detect Mycobacterium Para tuberculosis in a highly sensitive way. In addition, we will have a "state-of-the-art" DNA vaccine laboratory fully dedicated to the development of Johne's and Chron's disease therapeutic vaccines." GeneThera is planning to move to the new laboratory facility once space renovation is completed. The projected moving date is presently scheduled for March 31st 2016.
GENETHERA, INC. ISSUES COMMENTS ON THE FIRST INTERNATIONAL RESEARCH SYMPOSIUM ON MAP AND CROHN'S DISEASE.
GlobeNewswire - Tue Sep 29, 8:43AM CDT
GeneThera, Inc. (OTC: GTHR) as a service to its shareholders and the general public is pleased to release comments on the first Symposium on Mycobacterium Avium Paratuberculosis (MAP) and Crohn's disease, which was held on August 15 in Deerfield (IL). The Symposium entitled Game Changing Concepts in Crohn's Medicine was the first one ever held where scientists, physicians, Crohn's patients, family members and patient advocates gathered to discuss the link between MAP and Crohn's disease. Keynote Speakers were Dr. William Chamberlin, Las Cruces, NM; John Aiken, Laboratory Scientist from New Zealand; Dr. Amy Hermon-Taylor, a Family Physician from London, UK and daughter of Prof. John Hermon-Taylor, who pioneered the field of MAP and Crohn's Disease; Patrick McLean, Product Manager of RedHill Pharma (NASDAQ: RDHL), an Israel-based biopharmaceutical company; and Dr. Michael Collins, Professor of Veterinary Medicine at the University of Wisconsin in Madison. Proceedings of the Symposium are available at www.thecrohnsinfection.org
RDHL: 10.38 (+0.26)
MYCOBACTERIUM AVIUM PARATUBERCULOSIS (MAP) INFECTION: THE GLOBAL WARMING OF THE CATTLE INDUSTRY
GlobeNewswire - Mon Aug 03, 8:38AM CDT
Despite warnings from scientists who have shown unquestionable data that Earth climate has been changing due to human activities, governments and multinational corporations for years have denied scientific evidences. MAP infection in cattle draws many similarities with global warming. Despite the fact that MAP has been linked to several human diseases, governments, the cattle and dairy industry have continued to ignore scientific data and have not implemented any credible programs to control MAP infection. In the meantime, herd prevalence of MAP infection in cattle worldwide has reached alarming levels. More than 90% of dairy herds in the US are infected. In the UK, 50% of dairy herds are infected with MAP. A recent report from the Advisory Committee on Dangerous Pathogens (ACDP), a scientific advisory board of the UK Government, concluded that MAP potential for human infection exist and is not limited to Chron's Disease (CD). The ACDP report points out that genome analysis have suggested an association between MAP and several other inflammatory diseases besides CD. These diseases are:
GENETHERA APPOINTS TWO NEW MEMBERS ON ITS BOARD OF DIRECTORS
GlobeNewswire - Tue Apr 21, 10:54AM CDT
GeneThera Inc. (OTC:GTHR) announced today that has appointed Bruce Winsett and Jorgen Frandsen as members of the Company's Board of Directors
